



SCHRÖDINGER®


Ligand-based
Virtual Screening Methods



Virtual screening can quickly evaluate ligand libraries




Use different screening methods for different available data



Structure-based virtual screens

- Structure of Target
- Ligand-binding site known
- (optional) ligand/hit bound



Ligand-based virtual screens

- a single known hit
- multiple known hits
- (optional) active conformation

Virtual screen with many tools for best results


Pharmacophore
Based (Phase)

Structure Based
(Glide)

Similarity
Based (Shape,
Fingerprints)

- MM-GBSA
- AB-FEP
- FEP+


Screening Results




A pharmacophore is an abstract representation of interactions

A pharmacophore is the ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular interactions with a specific biological target and to trigger (or block) its biological response

-IUPAC



Pharmacophores are represented using features



- Common features
 - D for h-bond donor
 - A for h-bond acceptor
 - R for aromatic ring
 - H for hydrophobic
 - N for negative ionic
 - P for positive ionic
- D/A/R features have vector characteristics
- D/A features can be treated as projected points or vectors
- Can customize features

There are several ways to create pharmacophore hypotheses

Develop Pharmacophore Model

Create pharmacophore model using
Multiple Ligands (selected entries)

Actives/Inactives Split (of selected entries):
Actives: 38 | Inactives: 0 | Setup...

Pharmacophore method:
☒ Find best alignment and common features
☐ Use prealigned ligands (consensus model)

☒ Generate conformers | Options... | Settings...

Job name:
phase_pharm_3 | Run

From multiple active ligands

Host=localhost:1, Incorporate=append

Develop Pharmacophore Model

Create pharmacophore model using
Single Ligand (Workspace)

Choose features:
☒ A1 ☐ A2 ☐ A3 ☐ A4
☒ D5 ☐ H6 ☒ N7 ☐ P8
☐ R9 ☒ R10 ☐ R11

☒ Pick feature in workspace

☐ Add | Acceptor | in workspace | Settings...

Hypothesis Name:
Hypothesis_1 | Create

From one ligand conformation

Host=localhost, Incorporate=ignore

Develop Pharmacophore Model

Create pharmacophore model using
Receptor cavity (workspace)

Define the receptor binding site using:
☒ Centroid of residues
Specify Residues...
☐ X,Y,Z Coordinates
X: 78.06 | Y: 112.53 | Z: 18.87 | Settings...

Hypothesis Name:
hypothesis_2 | Run

From apo protein²

Host=localhost, Incorporate=ignore

Develop Pharmacophore Model

Create pharmacophore model using
Receptor-ligand complex (workspace)

Method:
☒ Manual ☐ Auto (E-Pharmacophore)

Choose ligand:
B:NVB (1133)
A:NVB (1133)

☐ Pick workspace ligand

Show features:
Fewer | More

Choose features:
☒ A2 ☐ A3 ☒ A6 ☒ A7
☒ D8

☒ Pick feature in workspace

☐ Add | Acceptor | in workspace | Excluded Volumes...



Hypothesis Name:
Hypothesis_2 | Create

From protein-ligand complex¹

Host=localhost:1, Incorporate=append

Shape screening makes use of known binders


- Hard sphere volume overlaps are used for similarity assessment
- Incorporate property information by allowing only atoms with similar types to match
- Sphere types
 - Heavy atom (shape only)
 - Heavy atom by element/atomtype (color)
 - Pharmacophore feature-located (color)
 - Hydrophobic ☐ Aromatic
 - Acceptor Donor
 - Negative ☐ Positive




CPU and GPU Shape screening are both useful

- Shape algorithm is primarily linear algebra
 - Same mathematical operations performed many times across different datasets
 - Small amount of data required per conformer compared

CPU	GPU
Small number of faster cores	Large number of slower cores
Works on a variety of tasks simultaneously	Optimized for taking huge batches of data and performing the same operation over and over very quickly



Generalized shape screening workflow




There are speed limitations to using 3D-based screening at scale

Method	Timings	Time to process 500M compounds on a single CPU or GPU	CPUs required to process 500M compounds in 7 days
Docking*	~10 sec/ligand	~158 years	~8200
Pharmacophore*	~5 ligands/sec @ 50 confs each	~3 years	~165
CPU Shape	~200 ligands/sec @ 10 confs each	~1 month	~4
GPU Shape	~10,500 ligands/sec @ 10 confs each	13 hours	NA


*Necessary Ionization/tautomeric expansion typically expands number of structures to be screened by 2.5X

Real & Virtual chemical screening libraries are growing substantially



Historically compound collections were comprised of already synthesized molecules with < 20 million compounds


Real & Virtual chemical screening libraries are growing substantially



GDB-17* with 166.4 billion compounds

All molecules with up to 17 atoms containing C, N, O, S,
and halogen atoms


Real & Virtual chemical screening libraries are growing substantially



Diverse, synthetically-tractable libraries are becoming common

- Multiple vendors with >100M synthesizable libraries
- 720M - Enamine REAL set (readiably accessible)
 - Synthesis success rates of 85% or higher reported


Real & Virtual chemical screening libraries are growing substantially



DNA encoded libraries of potentially trillions of compounds created combinatorially in one flask



Chemical screening libraries are growing substantially



DNA encoded libraries of potentially trillions of compounds created combinatorially in one flask



CADD can explore large chemical space, which can lead to new hits




Image from: https://en.wikipedia.org/wiki/Chemical_space

- 19.2 million structures
- the further away to points are, the more chemically distinct they are

Shoichet Hypothesis

- Chemical **diversity increases** with larger chemical space searching
- Shoichet hypothesis: As screening decks expand, **more tight binders** and **tighter binders** found



Questions? Email us at online-learning@schrodinger.com